CHOSA receives 94 tumour samples from US patients to validate Platin-DRP® in lung cancer chemo-immunotherapy

CHOSA Oncology received 94 tumour biopsy samples from Mount Sinai Hospital in New York for its ongoing research collaboration evaluating whether Platin-DRP® can identify advanced NSCLC patients most likely to benefit from platinum-based chemotherapy combined with immunotherapy. The samples, from patients treated with platinum chemotherapy and PD-1/PD-L1 inhibitors such as Keytruda and Opdivo, will undergo RNA analysis at CHOSA’s laboratory partner; no study results were reported.

Analysis

The key value inflection is not sample collection but whether Platin-DRP demonstrates predictive utility—identifying differential benefit from platinum plus immunotherapy—rather than merely correlating with outcomes in a selected cohort. RNA results from this collaboration could provide an early validation signal, but without disclosed endpoints, comparator groups, follow-up, and statistical performance, the 94 samples do not establish clinical utility or a commercial timeline.

Near term (days to weeks), treat this as a research milestone, not a revenue catalyst; any CHOSA repricing on the announcement alone risks getting ahead of evidence. Over 1–3 months, watch for analysis results and whether they support a prospective or independently replicated study. Over 6–18 months, a reproducible assay could help treatment selection and potentially support broader use of combination regimens, but adoption depends on clinical validation, workflow, reimbursement, and regulatory requirements. Failure to separate treatment benefit from general prognosis would undermine the thesis.

The read-through to Merck (Keytruda) and Bristol-Myers Squibb (Opdivo) is indirect and likely immaterial absent evidence that the assay changes treatment rates or outcomes at scale. A test that better identifies likely responders could support confidence in existing regimens; a test that rules patients out could instead constrain use. The market may be over-crediting the headline as proof of efficacy, while underappreciating that a validated selection tool could eventually improve treatment allocation. No directional trade is justified before results and study design are disclosed.

Key Decisions for Investors

• CHOSA: Avoid treating sample receipt as a fundamental catalyst; consider only event-driven exposure after reviewing the RNA-analysis results and validation design.
• Set a watch alert for disclosed endpoints, response/outcome comparisons, confidence intervals, assay reproducibility, and any prospective or independent validation. Weak separation from a prognostic baseline would falsify the clinical-utility thesis.
• BMY and MRK: No trade on this read-through. Reassess only if evidence indicates the assay materially changes eligible patient numbers, treatment selection, or outcomes for regimens involving Opdivo or Keytruda.